

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 May 2022 (27.05.2022)



(10) International Publication Number
WO 2022/108911 A1

(51) International Patent Classification:

A61P 17/14 (2006.01) A61K 47/24 (2006.01)
A61K 9/00 (2006.01) A61K 47/38 (2006.01)
A61K 9/10 (2006.01) A61K 9/107 (2006.01)
A61K 47/20 (2006.01) A61K 31/00 (2006.01)

(21) International Application Number:

PCT/US2021/059479

(22) International Filing Date:

16 November 2021 (16.11.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/114,887 17 November 2020 (17.11.2020) US
63/221,349 13 July 2021 (13.07.2021) US

(71) Applicant: **ARCUTIS BIOTHERAPEUTICS, INC.**
[US/US]; 3027 Townsgate Road, Suite #300, Westlake Vil-
lage, California 91361 (US).

(72) Inventors: **OSBORNE, David W.**; 4215 Creekside Court,
Fort Collins, Colorado 80525 (US). **TOFIG, Babak N.**; c/o
Arcutis Biotherapeutics, Inc., 3027 Townsgate Road, Suite
#300, Westlake Village, California 91361 (US).

(74) Agent: **POSTAL, Brett A.**; Rothwell, Figg, Ernst & Man-
beck, P.C., 607 14th Street NW, Suite 800, Washington,
District of Columbia 20005 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: COMPOSITIONS AND METHODS FOR DEEP DERMAL DRUG DELIVERY




FIG. 1

(57) Abstract: Pharmaceutical compositions for the topical administration of a drug to the pilosebaceous unit and methods for admin-
istering the same. As disclosed herein, the inventors of the present invention have made the surprising discovery that pharmaceutical
compositions comprising small particles of an active pharmaceutical ingredient and a silicone, such as dimethicone or cyclomethicone,
can be administered to the pilosebaceous unit. The pharmaceutical composition can comprise SHR0302 or spironolactone as an active
pharmaceutical ingredient.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*